Calamos Advisors LLC Sells 2,673 Shares of Amgen Inc. (NASDAQ:AMGN)

Calamos Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 3.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 73,299 shares of the medical research company’s stock after selling 2,673 shares during the period. Calamos Advisors LLC’s holdings in Amgen were worth $22,902,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Horizon Financial Services LLC purchased a new stake in shares of Amgen during the 1st quarter worth approximately $28,000. United Community Bank purchased a new stake in shares of Amgen in the fourth quarter worth about $29,000. Delos Wealth Advisors LLC boosted its position in shares of Amgen by 2,500.0% in the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 100 shares during the period. Bbjs Financial Advisors LLC bought a new stake in Amgen during the 2nd quarter worth approximately $33,000. Finally, Western Pacific Wealth Management LP bought a new position in shares of Amgen in the fourth quarter worth $37,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Price Performance

NASDAQ AMGN traded up $4.27 during trading on Friday, hitting $328.80. 1,771,092 shares of the stock traded hands, compared to its average volume of 2,582,902. The company has a market capitalization of $176.38 billion, a P/E ratio of 46.97, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. The firm has a 50-day simple moving average of $322.70 and a 200-day simple moving average of $299.54. The company has a quick ratio of 0.98, a current ratio of 1.42 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 12-month low of $248.38 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $5.00 earnings per share. As a group, analysts predict that Amgen Inc. will post 19.5 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.74%. Amgen’s payout ratio is currently 128.57%.

Analyst Ratings Changes

Several research firms recently commented on AMGN. Morgan Stanley reduced their target price on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a report on Thursday, July 11th. StockNews.com upgraded Amgen from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. Bank of America increased their target price on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Finally, Mizuho boosted their price objective on Amgen from $223.00 to $235.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Eleven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.